Table 3 Clinically significant adverse events
Solid tumours | Lymphoma | Myeloma | Overall | |
|---|---|---|---|---|
Thromboembolic events (%) | 3.74 | 1.10 | 5.0 | 3.49 |
Bleeding (%) | 2.64 | 1.47 | 1.25 | 2.38 |
Infection (%) | 4.23 | 8.82 | 6.88 | 5.04 |
Local intolerability (%) | 0.06 | 0.37 | 0.63 | 0.15 |
Rise in blood pressure (%) | 2.33 | 2.21 | 1.25 | 2.23 |
Other (%) | 9.14 | 7.72 | 8.75 | 8.92 |